Nanjing Medlander Medical Technology Co (SHSE:688273) PE Ratio without NRI: 38.99 (As of Jul. 15, 2026) — 53% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688273 Nanjing Medlander Medical Technology Co Ltd SHSE:688273
82 GF Score
Price ¥36.03
GF Value ¥35.36
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Nanjing Medlander Medical Technology Co PE Ratio without NRI?

Nanjing Medlander Medical Technology Co SHSE:688273 +3.09% 82 PE Ratio without NRI is 38.99 as of Jul. 15, 2026, which is 53% above its 10-year median of 25.53. GuruFocus rates SHSE:688273 with a GF Score™ of 82/100 and a GF Value™ of ¥35.36 (Fairly Valued). The stock has 7 warning signs investors should review. Among 450 Medical Devices & Instruments companies, Nanjing Medlander Medical Technology Co ranks worse than 73.33% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-15), Nanjing Medlander Medical Technology Co's share price is ¥36.03. Nanjing Medlander Medical Technology Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.92. Therefore, Nanjing Medlander Medical Technology Co's PE Ratio without NRI for today is 38.99.

During the past 8 years, Nanjing Medlander Medical Technology Co's highest PE Ratio without NRI was 52.92. The lowest was 16.82. And the median was 25.53.

Nanjing Medlander Medical Technology Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.92.

As of today (2026-07-15), Nanjing Medlander Medical Technology Co's share price is ¥36.03. Nanjing Medlander Medical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.88. Therefore, Nanjing Medlander Medical Technology Co's PE Ratio (TTM) for today is 41.13.

During the past years, Nanjing Medlander Medical Technology Co's highest PE Ratio (TTM) was 55.82. The lowest was 17.10. And the median was 26.64.

Nanjing Medlander Medical Technology Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥0.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.88.

Nanjing Medlander Medical Technology Co's EPS (Basic) for the three months ended in Mar. 2026 was ¥0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.88.


Nanjing Medlander Medical Technology Co  (SHSE:688273) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Nanjing Medlander Medical Technology Co PE Ratio without NRI Related Terms


Nanjing Medlander Medical Technology Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Nanjing Medlander Medical Technology Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Medlander Medical Technology Co PE Ratio without NRI Chart

Nanjing Medlander Medical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial N/A 30.50 46.59 28.09 51.73

Nanjing Medlander Medical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.63 28.94 35.62 51.73 40.64

SHSE:688273 vs ABT, SYK, MDT: PE Ratio without NRI Comparison

For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Medlander Medical Technology Co PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Nanjing Medlander Medical Technology Co's PE Ratio without NRI falls into.


SHSE:688273
82GF Score
Nanjing Medlander Medical Technology Co Ltd SHSE:688273
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Medlander Medical Technology Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Nanjing Medlander Medical Technology Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=36.03/0.924
=38.99

Nanjing Medlander Medical Technology Co's Share Price of today is ¥36.03.
Nanjing Medlander Medical Technology Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.92.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 38.99 mean?
Nanjing Medlander Medical Technology Co (SHSE:688273) has a PE Ratio without NRI of 38.99 as of Jul. 15, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Nanjing Medlander Medical Technology Co and its competitors. This is 53% above median its historical median of 25.53. Over the past decade, Nanjing Medlander Medical Technology Co's PE Ratio without NRI has ranged from 16.82 to 52.92. According to the industry distribution chart, Nanjing Medlander Medical Technology Co ranks #330 out of 450 companies in the Medical Devices & Instruments industry, placing it in the top 73.3%.
Is Nanjing Medlander Medical Technology Co's PE Ratio without NRI too high?
Nanjing Medlander Medical Technology Co's current PE Ratio without NRI of 38.99 is 53% above median its 10-year median of 25.53. Over the past 10 years, this metric has ranged from a low of 16.82 to a high of 52.92. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.70. Nanjing Medlander Medical Technology Co's value of 38.99 is 64.5% above this industry median. Based on the distribution chart, Nanjing Medlander Medical Technology Co ranks #330 out of 450 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's PE Ratio without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Medlander Medical Technology Co ranks #330 out of 450 companies for PE Ratio without NRI. This places Nanjing Medlander Medical Technology Co in the lower half of its industry. The industry median PE Ratio without NRI is 23.70. Nanjing Medlander Medical Technology Co's value of 38.99 is 64.5% above this benchmark. Historically, Nanjing Medlander Medical Technology Co's own PE Ratio without NRI has ranged from 16.82 to 52.92 over the past decade. While the company's 10-year median is 25.53 vs. the industry median of 23.70, Nanjing Medlander Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.70, based on 450 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current PE Ratio without NRI of 38.99 is 64.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current PE Ratio without NRI is 38.99, which is 53% above median its own 10-year median of 25.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Fairly Valued. The stock's GF Value™ is ¥35.36, compared to a current price of ¥36.03 — trading 1.9% above its estimated fair value. The current PE Ratio without NRI is 38.99, which is 53% above median its 10-year median of 25.53 and 64.5% above the Medical Devices & Instruments industry median of 23.70. Nanjing Medlander Medical Technology Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current PE Ratio without NRI is 38.99 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be overvalued. The current stock price of ¥36.03 is trading 1.9% above its estimated GF Value™ of ¥35.36. GuruFocus considers Nanjing Medlander Medical Technology Co to be Fairly Valued.

Key valuation signals for SHSE:688273:

  • PE Ratio without NRI: 38.99 (53% above median its 10-year median of 25.53)
  • GF Value™: ¥35.36 vs. price of ¥36.03 (1.9% above fair value)
  • GF Score™: 82/100 with 7 warning signs
  • Industry Position: 64.5% above the Medical Devices & Instruments median (#330 of 450)

No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanjing Medlander Medical Technology Co Business Description

Address Fengzhan Road, No. 32, Building A2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210012
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
82GF Score

Get the complete analysis for SHSE:688273

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.03
Price
¥35.36
GF Value